Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: A potential chemotherapeutic modality for primary effusion lymphoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Paul, Arun George ^a   Sharma Walia, Neelam ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN E; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; HYBRID PROTEIN; NIMESULIDE; PROTEIN CDC25C; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; PROTEIN P53 LANA 1 PROTEIN FUSION PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; SULFONAMIDE; TP53 PROTEIN, HUMAN;

APOPTOSIS; AQUAPORIN 3 GENE; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; KSHV GENE; MARKER GENE; PRIMARY EFFUSION LYMPHOMA; SYNDECAN 1 GENE; VITAMIN D3 RECEPTOR GENE; CELL SEPARATION; CELL SURVIVAL; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN HERPESVIRUS 8; METABOLISM; TIME; TUMOR CELL LINE;

HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; SULFONAMIDES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053583190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024379     Document Type: Article

References (53)

1. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF, (2009) HIV-associated lymphomas and gamma-herpesviruses. Blood 113: 1213-1224.
2. Ganem D, (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1: 273-296.
3. Klass CM, Offermann MK, (2005) Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 17: 447-455.
4. Curreli F, Friedman-Kien AE, Flore O, (2005) Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 115: 642-652.
5. An J, Sun Y, Fisher M, Rettig MB, (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18: 1699-1704.
6. Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, et al. (2001) Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene 20: 7029-7040.
7. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, et al. (2007) Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109: 2165-2173.
8. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, et al. (2007) Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 117: 1019-1028.
9. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM, (2001) Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. Aids 15: 280-282.
10. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, et al. (2005) Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 19: 473-476.
11. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M, (2006) A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 17: 1849-1850.
12. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, et al. (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463.
13. Wang D, Dubois RN, (2006) Prostaglandins and cancer. Gut 55: 115-122.
14. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, et al. (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507.
15. Bakhle YS, (2001) COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 134: 1137-1150.
16. de Groot DJ, van der Deen M, Le TK, Regeling A, de Jong S, et al. (2007) Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer 97: 1077-1083.
17. Kaur Saini M, Kaur J, Sharma P, Nath Sanyal S, (2009) Chemopreventive response of diclofenac, a non-steroidal anti-inflammatory drug in experimental carcinogenesis. Nutr Hosp 24: 717-723.
18. Liu JF, Zhu GJ, Jamieson GG, Wu TC, Zhu TN, et al. (2009) NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2. Cancer Invest 27: 17-23.
19. Renard JF, Julemont F, de Leval X, Pirotte B, (2006) The use of nimesulide and its analogues in cancer chemoprevention. Anticancer Agents Med Chem 6: 233-237.
20. Hull MA, (2005) Cyclooxygenase-2: how good is it as a target for cancer chemoprevention? Eur J Cancer 41: 1854-1863.
21. Sinha-Datta U, Taylor JM, Brown M, Nicot C, (2008) Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis 13: 33-40.
22. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM, (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1-20.
23. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, et al. (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105: 4784-4791.
24. Bernard MP, Bancos S, Sime PJ, Phipps RP, (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14: 2051-2060.
25. Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, et al. (2004) Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 64: 72-84.
26. George Paul A, Sharma-Walia N, Kerur N, White C, Chandran B, (2010) Piracy of prostaglandin E2/EP receptor-mediated signaling by Kaposi's sarcoma-associated herpes virus (HHV-8) for latency gene expression: strategy of a successful pathogen. Cancer Res 70: 3697-3708.
27. Sadagopan S, Sharma-Walia N, Veettil MV, Raghu H, Sivakumar R, et al. (2007) Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J Virol 81: 3949-3968.
28. Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, et al. (2010) Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog 6: e1000777.
29. Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, et al. (2006) Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 80: 6534-6552.
30. Li JY, Wang XZ, Chen FL, Yu JP, Luo HS, (2003) Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9: 915-920.
31. Davis R, Brogden RN, (1994) Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48: 431-454.
32. Nun TK, Kroll DJ, Oberlies NH, Soejarto DD, Case RJ, et al. (2007) Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus. Mol Cancer Ther 6: 2360-2370.
33. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP, (2010) Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma-associated Herpesvirus Lymphomas. J Virol 84: 3898-3908.
34. Su B, Chen S, (2009) Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Bioorg Med Chem Lett 19: 6733-6735.
35. Wen KW, Damania B, (2010) Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 289: 140-150.
36. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. (2003) A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9: 300-306.
37. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS, (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510.
38. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, et al. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423.
39. Aoki M, Kanamori M, Yudoh K, Ohmori K, Yasuda T, et al. (2001) Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma. Tumour Biol 22: 239-246.
40. Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, et al. (2003) Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101: 4115-4121.
41. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, et al. (2003) Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100: 10399-10404.
42. Wun T, McKnight H, Tuscano JM, (2004) Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 28: 179-190.
43. Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, et al. (2005) Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4: 571-582.
44. Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, et al. (2005) Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol 75: 212-220.
45. Sun Q, Matta H, Chaudhary PM, (2003) The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. Blood 101: 1956-1961.
46. Guasparri I, Wu H, Cesarman E, (2006) The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep 7: 114-119.
47. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ, (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402: 889-894.
48. Dormond O, Foletti A, Paroz C, Ruegg C, (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7: 1041-1047.
49. Bass MD, Morgan MR, Humphries MJ, (2009) Syndecans shed their reputation as inert molecules. Sci Signal 2: pe18.
50. Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V, (2010) The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 79: 1-9.
51. Verkman AS, Hara-Chikuma M, Papadopoulos MC, (2008) Aquaporins-new players in cancer biology. J Mol Med 86: 523-529.
52. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, et al. (2001) Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 7: 3178-3185.
53. Greenlee RT, Hill-Harmon MB, Murray T, Thun M, (2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15-36.